10 years of oral anticoagulant pharmacogenomics: What difference will it make? A critical appraisal

Pharmacogenomics

Volumn 10, Issue 12, 2009, Pages 1955-1965

  Kurnik, Daniel ^a,b   Loebstein, Ronen ^a,b   Halkin, Hillel ^a,b   Gak, Eva ^b,c   Almog, Shlomo ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

Author keywords

CYP2C9; Dosing algorithm; Oral anticoagulants; Personalized medicine; Pharmacogenetics; Pharmacogenomics; VKORC1; Warfarin

Indexed keywords

ACENOCOUMAROL; COUMARIN ANTICOAGULANT; CYTOCHROME P450 2C9; OXIDOREDUCTASE; PHENPROCOUMON; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG SENSITIVITY; DRUG TARGETING; DRUG UTILIZATION; ETHNIC DIFFERENCE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; PHARMACOGENOMICS; REVIEW; STEADY STATE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS;

EID: 73649109224     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.149     Document Type: Review

References (65)

1. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (9154), 717-719 (1999). First clinical study of warfarin pharmacogenetics.
2. Roden DM, Stein CM: Clopidogrel and the concept of high-risk pharmacokinetics. Circulation 119(16), 2127-2130 (2009).
3. Ansell J, Hirsh J, Hylek E et al.: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), S160-S198 (2008). Comprehensive guide to clinical anticoagulation.
4. Wysowski DK, Nourjah P, Swartz L: Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch. Intern. Med. 167(13), 1414-1419 (2007).
5. Linkins LA, Choi PT, Douketis JD: Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann. Intern. Med. 139(11), 893-900 (2003).
6. Cios DA, Baker WL, Sander SD, Phung OJ, Coleman CI: Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: a meta-analysis. Am. J. Health Syst. Pharm. 66(10), 916-925 (2009).
7. Hylek EM, Go AS, Chang Y et al.: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 349(11), 1019-1026 (2003).
8. Klein TE, Altman RB, Eriksson N et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009). Pharmacogenetic dose-prediction model derived from the largest international cohort.
9. Wadelius M, Chen LY, Lindh JD et al.: The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4), 784-792 (2009). Pharmacogenetic dose-prediction model derived from the largest prospective cohort incorporating many candidate gene variants.
10. Landefeld CS, Goldman L: Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am. J. Med. 87(2), 144-152 (1989).
11. Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R: Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin. Pharmacol. Ther. 15(4), 424-430 (1974).
12. Rettie AE, Korzekwa KR, Kunze KL et al.: Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5(1), 54-59 (1992).
13. Kaminsky LS, Zhang ZY: Human P450 metabolism of warfarin. Pharmacol. Ther. 73(1), 67-74 (1997).
14. Takahashi H, Echizen H: Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J. 3(4), 202-214 (2003).
15. Scordo MG, Pengo V, Spina E et al.: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 72(6), 702-710 (2002).
16. Loebstein R, Yonath H, Peleg D et al.: Interindividual variability in sensitivity to warfarin - nature or nurture? Clin. Pharmacol. Ther. 70(2), 159-164 (2001).
17. Kirchheiner J, Brockmoller J: Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77(1), 1-16 (2005).
18. Lindh JD, Holm L, Andersson ML, Rane A: Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 65(4), 365-375 (2009).
19. Sanderson S, Emery J, Higgins J: CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 7(2), 97-104 (2005).
20. Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL: An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb. Haemost. 100(2), 229-239 (2008).
21. Limdi NA, McGwin G, Goldstein JA et al.: Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther. 83(2), 312-321 (2008). Comparison of warfarin pharmacogenetics between American whites and blacks.
22. Tai G, Farin F, Rieder MJ et al.: In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet. Genomics 15(7), 475 481 (2005).
23. Scott SA, Jaremko M, Lubitz SA et al.: CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 10(8), 1243-1255 (2009).
24. Veenstra DL, Blough DK, Higashi MK et al.: CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin. Pharmacol. Ther. 77(5), 353-364 (2005).
25. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 14(12), 813-822 (2004).
26. Beinema M, Brouwers JR, Schalekamp T, Wilffert B: Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb. Haemost. 100(6), 1052-1057 (2008).
27. Teichert M, Eijgelsheim M, Rivadeneira F et al.: A genome-wide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet. 18(19), 3758-3768 (2009).
28. Stehle S, Kirchheiner J, Lazar A, Fuhr U: Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin. Pharmacokinet. 47(9), 565-594 (2008). Systemic review of coumarin pharmacogenetics.
29. Teichert M, van Schaik RH, Hofman A et al.: Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin. Pharmacol. Ther. 85(4), 379-386 (2009).
30. Rost S, Fregin A, Ivaskevicius V et al.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974), 537-541 (2004). First report of the effect of rare VKORC1 variants on coagulation.
31. Li T, Chang CY, Jin DY et al.: Identification of the gene for vitamin K epoxide reductase. Nature 427(6974), 541-544 (2004). Identification of the VKORC1 gene.
32. D'Andrea G, D'Ambrosio RL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2), 645-649 (2005). First study to show the effect of common VKORC1 variants on warfarin dose requirements.
33. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005). VKORC1 haplotype structure and haplotype effects on dose requirement.
34. Geisen C, Watzka M, Sittinger K et al.: VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 94(4), 773-779 (2005).
35. Wang D, Chen H, Momary KM et al.: Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112(4), 1013-1021 (2008).
36. Limdi NA, Beasley TM, Crowley MR et al.: VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9(10), 1445-1458 (2008).
37. Schwarz UI, Ritchie MD, Bradford Y et al.: Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358(10), 999-1008 (2008). Examines the effect of CYP2C9 and VKORC1 variants during warfarin initiation.
38. Wadelius M, Pirmohamed M: Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 7(2), 99-111 (2007).
39. Cooper GM, Johnson JA, Langaee TY et al.: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112(4), 1022-1027 (2008). First genome-wide association study of warfarin dose requirements.
40. Takeuchi F, McGinnis R, Bourgeois S et al.: A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), E1000433 (2009).
41. Caldwell MD, Awad T, Johnson JA et al.: CYP4F2 genetic variant alters required warfarin dose. Blood 111(8), 4106-4112 (2008). First report identifying the effect of a CYP4F2 variant on warfarin sensitivity.
42. Borgiani P, Ciccacci C, Forte V et al.: CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10(2), 261-266 (2009).
43. McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE: CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol. 75(6), 1337-1346 (2009).
44. Perez-Andreu V, Roldan V, Anton AI et al.: Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 113(20), 4977-4979 (2009).
45. Loebstein R, Dvoskin I, Halkin H et al.: A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109(6), 2477-2480 (2007). First study identifying a common variant associated with relative warfarin resistance in a specific population.
46. Aklillu E, Leong C, Loebstein R, Halkin H, Gak E: VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood 111(7), 3903-3904 (2008).
47. Scott SA, Edelmann L, Kornreich R, Desnick RJ: Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am. J. Hum. Genet. 82(2), 495-500 (2008).
48. Takahashi H, Wilkinson GR, Nutescu EA et al.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16(2), 101-110 (2006).
49. Gage BF, Eby C, Johnson JA et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
50. Wu AH: Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics 8(7), 851-861 (2007).
51. Lazo-Langner A, Monkman K, Kovacs MJ: Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram. J. Thromb. Haemost. 7(8), 1276-1283 (2009).
52. Millican EA, Lenzini PA, Milligan PE et al.: Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110(5), 1511-1515 (2007). First pharmacogenetic dose-predicting algorithm including early international normalized ratio values.
53. Michaud V, Vanier MC, Brouillette D et al.: Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin. Pharmacol. Ther. 83(5), 740-748 (2008).
54. Li C, Schwarz UI, Ritchie MD et al.: Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 113(17), 3925-3930 (2009). First systemic assessment of the incremental value of genetic variables on dose prediction after incorporating international normalized ratio values during warfarin initiation.
55. Lenzini PA, Grice GR, Milligan PE et al.: Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J. Thromb. Haemost. 6(10), 1655-1662 (2008).
56. Flockhart DA, O'Kane D, Williams MS et al.: Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet. Med. 10(2), 139-150 (2008).
57. Rosove MH, Grody WW: Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann. Intern. Med. 151(4), 270-273, W95 (2009).
58. Becquemont L: Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. Eur. J. Clin. Pharmacol. 64(10), 953-960 (2008).
59. Caraco Y, Blotnick S, Muszkat M: CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther. 83(3), 460-470 (2008). Randomized controlled trial of CYP2C9-guided warfarin initiation.
60. Anderson JL, Horne BD, Stevens SM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007). First randomized controlled trial of pharmacogenetic-guided warfarin initiation.
61. Garcia DA, Witt DM, Hylek E et al.: Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann. Pharmacother. 42(7), 979-988 (2008). Comprehensive policy to improve the safety and efficacy of coumarin therapy.
62. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee www.imm.ki.se/CYPalleles/cyp2c9.htm
63. Warfarin dosing www.warfarindosing.org
64. ClincalTrials.gov: a service of the US NIH www.clinicaltrials.gov
65. Pharmacogenomics knowledge base www.PharmGKB.org